学霸夫妻港交所敲钟，福州多了一家上市公司！

Core Viewpoint - Haixi New Drug successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for the company and the local biopharmaceutical industry [2][21]. Company Overview - Haixi New Drug, founded by a couple with strong academic backgrounds, has developed four core generic drugs and has a unique dual-track model combining generic and innovative drugs [9][15]. - The company was established in collaboration with three state-owned asset platforms in Fujian province [18]. Listing Process - The company initially planned to list on October 17 but delayed the listing due to the need for additional time to finalize announcements and obtain regulatory approval [4][5]. - Haixi New Drug became the first new stock to experience a delayed listing after dark pool trading under the FINI system in Hong Kong [6]. Stock Performance - The stock opened at 102 HKD, a 18.06% increase from the issue price of 86.4 HKD, and reached 110.2 HKD by midday, representing a 27.5% increase [2]. - The stock's trading volume reached 219 million HKD on the first day [2]. Financial Performance - The company has achieved profitability, with revenue projected to grow from 212.5 million RMB in 2022 to 466.7 million RMB in 2024, and net profit expected to rise from 68.98 million RMB to 136.08 million RMB in the same period [17][25]. - The four core generic drugs contribute over 90% of the company's revenue, with projected revenues for 2024 from these drugs totaling approximately 4.5 billion RMB [17]. Future Plans - The company plans to use the net proceeds of 940 million HKD from the IPO to enhance its research and development capabilities and expand its product pipeline [26]. - Haixi New Drug has four innovative drugs in early clinical stages, with the most advanced candidate targeting osteosarcoma expected to enter Phase III trials by the second half of 2025 [28].